A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard said the British tanker, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
The pharmaceutical and health-care industry needs reform "far more sweeping" than what Dodd-Frank did for the financial industry, former Vermont governor Howard Dean said Friday.
His remarks were in response to the recent controversy over Mylan's $608 EpiPen.
"We pay for medicine on a fee-for-service basis in this country. As long as we keep doing that, we're going to keep encouraging this kind of stuff," Dean, who is also a doctor, said in an interview with CNBC's "Power Lunch. "
Fee-for-service medicine is a method where health-care providers are paid for each service performed on a patient. Critics say the payment model pushes up costs.
"You pay us to do as much as we possibly can whether it works or not," said Dean. "The only way you are going to get budgetary predictability by the payers, both private and public, is to get rid of fee-for-service medicine and do all this . . . at a capitated basis."
On Thursday, Mylan CEO Heather Bresch addressed EpiPen's repeated price hikes in an interview with CNBC. She said she was "frustrated" and said middlemen added to the ultimate cost.
She also said she hoped the issue was an inflection point for the country.
"Our health care is in crisis. It's no different than the mortgage financial crisis back in 2007," Bresch said.
Despite his calls for changes in the health-care system, Dean wasn't indicting the entire pharma industry. He called Bresch an "outlier CEO."
"This is predatory behavior by a particular drug company, and there's really not an excuse for it. I don't see the other pharmaceutical companies doing this kind of predatory behavior and these kinds of outrageous price increases," said Dean.